The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 17, 2019

Filed:

Nov. 01, 2017
Applicant:

Iovance Biotherapeutics, Inc., San Carlos, CA (US);

Inventors:

Anand Veerapathran, Tampa, FL (US);

Aishwarya Gokuldass, Chennai, IN;

Brian Rabinovich, Winchester, MA (US);

Michael T. Lotze, Pittsburgh, PA (US);

Assignee:

Iovance Biotherapeutics, Inc., San Carlos, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); C12N 5/0781 (2010.01); C12N 5/0784 (2010.01); C12N 5/078 (2010.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); C07K 16/42 (2006.01);
U.S. Cl.
CPC ...
C12N 5/0635 (2013.01); A61K 39/0011 (2013.01); A61P 35/00 (2018.01); C07K 14/70532 (2013.01); C07K 14/70575 (2013.01); C07K 16/4283 (2013.01); C12N 5/065 (2013.01); C12N 5/0639 (2013.01); A61K 2039/515 (2013.01); A61K 2039/5158 (2013.01); C07K 2317/622 (2013.01); C12N 2501/06 (2013.01); C12N 2501/2302 (2013.01); C12N 2501/25 (2013.01); C12N 2501/51 (2013.01); C12N 2501/515 (2013.01); C12N 2501/998 (2013.01); C12N 2502/11 (2013.01); C12N 2502/99 (2013.01);
Abstract

In some embodiments, compositions and methods relating to isolated artificial antigen presenting cells (aAPCs) are disclosed, including aAPCs comprising a myeloid cell transduced with one or more viral vectors, such as a MOLM-14 or a EM-3 myeloid cell, wherein the myeloid cell endogenously expresses HLA-AB/C, ICOS-L, and CD58, and wherein the one or more viral vectors comprise a nucleic acid encoding CD86 and a nucleic acid encoding 4-1BBL and/or OX40L and transduce the myeloid cell to express CD86 and 4-1BBL and/or OX40L proteins. In some embodiments, methods of expanding tumor infiltrating lymphocytes (TILs) with aAPCs and methods of treating cancers using TILs after expansion with aAPCs are also disclosed.


Find Patent Forward Citations

Loading…